Clinical Trials Browser

Approved for marketing × AZD 6244 × Clear all

NCT03259633 2020-05-01

An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1

Approved for marketing

Neurofibroma, Plexiform